Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience
Autoimmune adverse effects of immune checkpoint inhibitors (ICIs) are rare but may be life-threatening. We performed a retrospective analysis of the immune-related adverse effects (irAEs) of ICIs in the Masaryk Memorial Cancer Institute (MMCI) from 2011 to 2021. The ICIs were administered to 648 pat...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2022-06-01
|
| Series: | European Pharmaceutical Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/afpuc-2022-0006 |
| _version_ | 1818017969999970304 |
|---|---|
| author | Juřica Jan Goněc Roman Bártová Adela Gregorová Jana |
| author_facet | Juřica Jan Goněc Roman Bártová Adela Gregorová Jana |
| author_sort | Juřica Jan |
| collection | DOAJ |
| description | Autoimmune adverse effects of immune checkpoint inhibitors (ICIs) are rare but may be life-threatening. We performed a retrospective analysis of the immune-related adverse effects (irAEs) of ICIs in the Masaryk Memorial Cancer Institute (MMCI) from 2011 to 2021. The ICIs were administered to 648 patients. Severe irAEs were pronounced in 83 patients (12.8 %). Further, we report a case of severe irAE after treatment with ipilimumab and nivolumab. Prednisone, mesalazine, octreotide, infliximab, vedolizumab, and mycophenolate mofetil were used to manage G4 colitis, with partial response. Early diagnosis and appropriate management of irAE are essential in the perspective of further oncological treatment. |
| first_indexed | 2024-04-14T07:33:47Z |
| format | Article |
| id | doaj.art-37610939435b460e8d2c8f8031bac89e |
| institution | Directory Open Access Journal |
| issn | 2453-6725 |
| language | English |
| last_indexed | 2024-04-14T07:33:47Z |
| publishDate | 2022-06-01 |
| publisher | Sciendo |
| record_format | Article |
| series | European Pharmaceutical Journal |
| spelling | doaj.art-37610939435b460e8d2c8f8031bac89e2022-12-22T02:05:45ZengSciendoEuropean Pharmaceutical Journal2453-67252022-06-0169s1848610.2478/afpuc-2022-0006Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical ExperienceJuřica Jan0Goněc Roman1Bártová Adela2Gregorová Jana3Faculty of Medicine, Department of Pharmacology, Masaryk University, Brno, Czech RepublicMasaryk Memorial Cancer Institute, Brno, Czech RepublicFaculty of Medicine, Department of Pharmacology, Masaryk University, Brno, Czech RepublicFaculty of Medicine, Department of Biochemistry, Masaryk University, Brno, Czech RepublicAutoimmune adverse effects of immune checkpoint inhibitors (ICIs) are rare but may be life-threatening. We performed a retrospective analysis of the immune-related adverse effects (irAEs) of ICIs in the Masaryk Memorial Cancer Institute (MMCI) from 2011 to 2021. The ICIs were administered to 648 patients. Severe irAEs were pronounced in 83 patients (12.8 %). Further, we report a case of severe irAE after treatment with ipilimumab and nivolumab. Prednisone, mesalazine, octreotide, infliximab, vedolizumab, and mycophenolate mofetil were used to manage G4 colitis, with partial response. Early diagnosis and appropriate management of irAE are essential in the perspective of further oncological treatment.https://doi.org/10.2478/afpuc-2022-0006immune checkpoint inhibitorsimmunotherapyadverse effectautoimmunity |
| spellingShingle | Juřica Jan Goněc Roman Bártová Adela Gregorová Jana Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience European Pharmaceutical Journal immune checkpoint inhibitors immunotherapy adverse effect autoimmunity |
| title | Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience |
| title_full | Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience |
| title_fullStr | Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience |
| title_full_unstemmed | Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience |
| title_short | Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience |
| title_sort | immune mediated adverse effects of checkpoint inhibitors a clinical experience |
| topic | immune checkpoint inhibitors immunotherapy adverse effect autoimmunity |
| url | https://doi.org/10.2478/afpuc-2022-0006 |
| work_keys_str_mv | AT juricajan immunemediatedadverseeffectsofcheckpointinhibitorsaclinicalexperience AT gonecroman immunemediatedadverseeffectsofcheckpointinhibitorsaclinicalexperience AT bartovaadela immunemediatedadverseeffectsofcheckpointinhibitorsaclinicalexperience AT gregorovajana immunemediatedadverseeffectsofcheckpointinhibitorsaclinicalexperience |